🐦 推特Wall St EngineQwen · 实盘不做把握 3/10不做原因:风险收益比不佳
北京时间·🕒 发布 19:01:08时区推断·⟳ 抓取 19:01:23·⚡ 决策 09-01 19:15:40 +14m17s·55.9 天前
美敦力FY27Q1业绩超预期并小幅上调全年指引，含额外财政周约5.7亿美元收入贡献
超大市值(~$150B)主标的，季度beat仅2-4%且被额外财政周($570M)显著膨胀，FY27指引上调极小(EPS中值+$0.02)，相对市值无足够增量支撑短线交易。A股/港股已收盘且无直接二阶映射机会。案例库同日同事件已判AVOID。
📄 原文Wall St Engine@wallstengine↗ 原文
MEDTRONIC $MDT Q1’27 EARNINGS HIGHLIGHTS 🔹 Revenue: $9.76B (Est. $9.54B) 🟢; +13.7% YoY 🔹 Adj. EPS: $1.45 (Est. $1.39) 🟢…
不做 美敦力（MDT.US）
超大市值(~$150B+)，季度beat 2-4%被额外财政周($570M)显著膨胀，FY27指引上调极小(中值+$0.02)，相对市值无足够增量；美股盘前无法成交，且即使开盘后该幅度也不构成正期望短线交易
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Medtronic FY27Q1收入$9.76B超共识2.3%、EPS $1.45超4.3%，但公司披露额外财政周贡献约$570M收入，扣除后beat幅度大幅缩水。FY27 EPS指引从$5.90-$6.00仅上调至$5.94-$6.00(中值+$0.02)，有机增速指引上调50bp。对~$150B市值而言，这一增量不足以构成短线交易催化。$700M Cornerstone Robotics合作为分销权协议，非变革性并购。无明确二阶A股/港股映射机会。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 high · price-in 风险 medium ↗
主要风险
- 额外财政周($570M)使表观增长显著高于底层有机增速，市场可能对此打折定价
反向证据
- 做多前查反向 · 来源 事件正文分析 · 日期 2026-09-01 · 影响 invalidates
公司自身披露额外财政周贡献约$570M有机增长，显著膨胀表观增速；FY27 EPS指引中值仅上调$0.02，对$150B+市值增量极小
检索:MDT earnings extra fiscal week impact guidance raise materiality
先例如何影响了这次决策
对本次决策的影响:先例不足不改变AVOID结论，因为核心问题是materiality不足而非方向不确定
方向:超大市值医疗器械公司季度小幅超预期，历史反应通常+0.5%~+2%，不构成高胜率短线交易
涨幅量级:无高相似先例校准，但基于市值和beat幅度的基本逻辑判断增量不足
工具执行结果 · 成功 3 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 912 ms
{"result": "search_processed_events:agent query=`medtronic cornerstone robotics 合作 | medtronic mdt q1 fy2027 earnings | medtronic 财报 收入超预期 | 美敦力 业绩 上调指引`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 61.7/72 小时、2080 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - fetch_decision_experience 成功 stock_tools HTTP · 1,711 ms
{ - stock_quote 降级 stock_tools HTTP · 1,970 ms
取价失败: Futu returned no quote - search_case_library 成功 stock_tools HTTP · 776 ms
{"result": "search_case_library「MDT.US」—— 与这些标的相关的自家决策案例(本页 12 条,该标的全历史相关记录共 34 条；ENTER 只按该标的自己的腿统计):\n◆ MDT.US：相关历史决策 34 条 · 其中该标的 ENTER 1 条(2.9%) · 已结算 1 笔 · 胜率 100% · 中位 +1.15% · 均值 +1.15% ⚠️只有 1 笔,样本太薄,只能当线索不能当规律\n↑ 胜率/收益口径:ENTER 当日之后 T+1 开盘入场、次日开盘出场,做空腿已按方向取反(所以正数=这个方向做对了)。统计的只有★那只票自己的腿。\n【对所查标
原文全文
展开原文 · 1,590 字
MEDTRONIC $MDT Q1’27 EARNINGS HIGHLIGHTS
🔹 Revenue: $9.76B (Est. $9.54B) 🟢; +13.7% YoY
🔹 Adj. EPS: $1.45 (Est. $1.39) 🟢; +15.1% YoY
🔹 Cardiac Ablation Solutions: +88% YoY
🔸 Announces ~$700M Cornerstone Robotics deal
Raises FY27 Guide:
🔹 Adj. EPS: $5.94-$6.00 (Est. $5.95) 🟢
🔹 Organic Growth: 7.25%-7.75%; from 6.75%-7.25%
Segment Revenue:
🔹 Cardiovascular: $3.9B; +19.5% YoY
🔹 Neuroscience: $2.7B; +10.3% YoY
🔹 Medical Surgical: $2.3B; +10.0% YoY
🔹 Diabetes: $843M; +16.9% YoY
Other Q1 Metrics:
🔹 Non-GAAP Operating Margin: 23.7%; +10 bps YoY
🔹 GAAP Oper Margin: 18.1%; +120 bps YoY
🔹 Free Cash Flow: $1.3B
Key Updates:
🔸 ~$700M Cornerstone Robotics partnership: rights to distribute the Sentire surgical robot in select markets outside the U.S., alongside its Hugo system; Hugo procedures expected to exceed 50,000 globally by fiscal year-end
🔸 Q1 included an extra fiscal week, a ~$570M benefit to organic growth per the company
🔸 FY27 EPS guide raised from prior $5.90-$6.00
🔸 Closed Scientia Vascular and SPR Therapeutics acquisitions; new strategic investment in Pi-Cardia
🔸 Affera CE Mark expanded to ventricular arrhythmias; FDA cleared next-gen Touch Surgery Aide platform
Comments:
🔸 “The combination of strong operating performance and disciplined financial management drove revenue and adjusted EPS ahead of expectations, enabling us to raise our fiscal 2027 guidance.”
🔸 “What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platforms”
🔹 Revenue: $9.76B (Est. $9.54B) 🟢; +13.7% YoY
🔹 Adj. EPS: $1.45 (Est. $1.39) 🟢; +15.1% YoY
🔹 Cardiac Ablation Solutions: +88% YoY
🔸 Announces ~$700M Cornerstone Robotics deal
Raises FY27 Guide:
🔹 Adj. EPS: $5.94-$6.00 (Est. $5.95) 🟢
🔹 Organic Growth: 7.25%-7.75%; from 6.75%-7.25%
Segment Revenue:
🔹 Cardiovascular: $3.9B; +19.5% YoY
🔹 Neuroscience: $2.7B; +10.3% YoY
🔹 Medical Surgical: $2.3B; +10.0% YoY
🔹 Diabetes: $843M; +16.9% YoY
Other Q1 Metrics:
🔹 Non-GAAP Operating Margin: 23.7%; +10 bps YoY
🔹 GAAP Oper Margin: 18.1%; +120 bps YoY
🔹 Free Cash Flow: $1.3B
Key Updates:
🔸 ~$700M Cornerstone Robotics partnership: rights to distribute the Sentire surgical robot in select markets outside the U.S., alongside its Hugo system; Hugo procedures expected to exceed 50,000 globally by fiscal year-end
🔸 Q1 included an extra fiscal week, a ~$570M benefit to organic growth per the company
🔸 FY27 EPS guide raised from prior $5.90-$6.00
🔸 Closed Scientia Vascular and SPR Therapeutics acquisitions; new strategic investment in Pi-Cardia
🔸 Affera CE Mark expanded to ventricular arrhythmias; FDA cleared next-gen Touch Surgery Aide platform
Comments:
🔸 “The combination of strong operating performance and disciplined financial management drove revenue and adjusted EPS ahead of expectations, enabling us to raise our fiscal 2027 guidance.”
🔸 “What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platforms”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。